Salim Syed
Stock Analyst at Mizuho
(1.92)
# 1,462
Out of 4,608 analysts
71
Total ratings
40.74%
Success rate
-9.46%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Salim Syed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte | Maintains: Outperform | $113 → $163 | $114.25 | +42.67% | 3 | Sep 10, 2024 | |
| ATRA Atara Biotherapeutics | Upgrades: Outperform | $25 → $18 | $7.61 | +136.53% | 4 | Aug 16, 2024 | |
| BIIB Biogen | Maintains: Outperform | $277 → $251 | $188.74 | +32.99% | 14 | Aug 6, 2024 | |
| WVE Wave Life Sciences | Reiterates: Outperform | $19 | $8.83 | +115.18% | 4 | Jun 25, 2024 | |
| AMGN Amgen | Maintains: Neutral | $223 → $235 | $319.73 | -26.50% | 7 | May 9, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $34 | $25.30 | +34.39% | 1 | Apr 9, 2024 | |
| NKTX Nkarta | Maintains: Buy | $31 → $25 | $4.17 | +499.52% | 6 | Mar 22, 2024 | |
| CYTK Cytokinetics | Maintains: Buy | $103 → $99 | $52.61 | +88.18% | 5 | Mar 6, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $82 → $99 | $45.71 | +116.58% | 3 | Mar 6, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $60 → $53 | $25.08 | +111.32% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $90 | $84.74 | +6.21% | 5 | Feb 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $6 | $1.43 | +319.58% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $1.02 | +1,958.82% | 5 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $168 → $36 | $14.65 | +145.73% | 1 | Nov 16, 2022 |
Vaxcyte
Sep 10, 2024
Maintains: Outperform
Price Target: $113 → $163
Current: $114.25
Upside: +42.67%
Atara Biotherapeutics
Aug 16, 2024
Upgrades: Outperform
Price Target: $25 → $18
Current: $7.61
Upside: +136.53%
Biogen
Aug 6, 2024
Maintains: Outperform
Price Target: $277 → $251
Current: $188.74
Upside: +32.99%
Wave Life Sciences
Jun 25, 2024
Reiterates: Outperform
Price Target: $19
Current: $8.83
Upside: +115.18%
Amgen
May 9, 2024
Maintains: Neutral
Price Target: $223 → $235
Current: $319.73
Upside: -26.50%
Enliven Therapeutics
Apr 9, 2024
Initiates: Buy
Price Target: $34
Current: $25.30
Upside: +34.39%
Nkarta
Mar 22, 2024
Maintains: Buy
Price Target: $31 → $25
Current: $4.17
Upside: +499.52%
Cytokinetics
Mar 6, 2024
Maintains: Buy
Price Target: $103 → $99
Current: $52.61
Upside: +88.18%
CRISPR Therapeutics AG
Mar 6, 2024
Maintains: Buy
Price Target: $82 → $99
Current: $45.71
Upside: +116.58%
BridgeBio Pharma
Mar 5, 2024
Maintains: Buy
Price Target: $60 → $53
Current: $25.08
Upside: +111.32%
Feb 22, 2024
Maintains: Buy
Price Target: $101 → $90
Current: $84.74
Upside: +6.21%
Mar 28, 2023
Maintains: Buy
Price Target: $12 → $6
Current: $1.43
Upside: +319.58%
Nov 16, 2022
Maintains: Buy
Price Target: $28 → $21
Current: $1.02
Upside: +1,958.82%
Nov 16, 2022
Maintains: Buy
Price Target: $168 → $36
Current: $14.65
Upside: +145.73%